Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers
Pharmaceutics · 14.10.2025 · 17 (10) · 1330
DOI: 10.3390/pharmaceutics17101330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 14.10.2025. Verfasst von Samuel Arca und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Chemo-Biologie Synthétique & Thérapeutique, Faculté de Pharmacie, UMR 7199 CNRS, Université de Strasbourg, 67400 Illkirch, France. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Blanche pour Vaincre la Mucoviscidose » and Association Vaincre la Mucoviscidose, Blanche pour Vaincre la Mucoviscidose, Association Vaincre la Mucoviscidose.
Abstract (Originalsprache)
Background/Objectives: Local delivery of gene therapy products through the airways shows great promise for the treatment of a number of serious lung diseases, but its effectiveness is hampered by the mucus layer protecting the lung epithelium in the trachea and bronchi.
Methods
To overcome this barrier, we engineered carbon dots (CDs) with mucus penetrating properties.
Results
The CDs were synthesized by solvothermal treatment of citric acid and branched polyethyleneimine, and functionalized with maleamic acid groups to create cationic mucoinert nanoparticles with tunable charge. We characterized their interactions with a mucus model through turbidity and transport measurements, and assessed their impact on the viscoelastic properties of the biopolymer. We then demonstrated that the carriers are effective at delivering pDNA to a variety of cell models in vitro. In particular, mucus-producing Calu-3 cells cultured at the air–liquid interface (ALI) were used as a discriminating model to evaluate intracellular delivery of the genetic cargo through a thick layer of mucus at the cell surface.
Conclusions
The functionalization of CDs with maleamic acid groups resulted in a 1000- to 10,000-fold increase in transfection efficiency in the mucus-producing model, offering new opportunities for lung gene therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire de Chemo-Biologie Synthétique & Thérapeutique, Faculté de Pharmacie, UMR 7199 CNRS, Université de Strasbourg, 67400 Illkirch, France.
ORCID-Profile: Luc Lebeau
Förderung
- Blanche pour Vaincre la Mucoviscidose » and Association Vaincre la Mucoviscidose
- Blanche pour Vaincre la Mucoviscidose
- Association Vaincre la Mucoviscidose
Zitieren
APA
Arca, S., Witjaksono, C., Pons, F., & Lebeau, L. (2025). Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers. Pharmaceutics, 17(10), 1330. https://doi.org/10.3390/pharmaceutics17101330
Vancouver
Arca S, Witjaksono C, Pons F, Lebeau L. Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers. Pharmaceutics. 2025;17(10):1330. doi:10.3390/pharmaceutics17101330
BibTeX
@article{Arca2025,
author = {Arca, Samuel and Witjaksono, Clea and Pons, Françoise and Lebeau, Luc},
title = {Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1330},
doi = {10.3390/pharmaceutics17101330}
}
EUVIMED